Seven peptidyl proteasome inhibitors were tested for in vitro activity against Trypanosoma brucei bloodstream forms. Two compounds showed activity in the low nanomolar range. In general, trypanosomes were more susceptible to the compounds than were human HL-60 cells. The data support the potential of proteasome inhibitors for rational antitrypanosomal drug development.
Trypanosoma brucei is the causative agent of human sleeping sickness in Africa. Over 60 million persons are at risk of acquiring the infection, and approximately 50,000 new cases are reported annually (21) . If left untreated, the disease is fatal. For chemotherapy of sleeping sickness only four drugs, with serious side effects, are available (5) . Therefore, the identification of novel targets for chemotherapy is urgently required if new treatments of the disease are to be developed.
The proteasome is a multicatalytic proteinase complex which plays a critical role in intracellular protein degradation (4) . Inhibitors of the proteasome have recently received attention as a novel class of anticancer drugs (2, 8, 12, 15, 17) . However, drugs developed as potential antitumor agents could also be of use against sleeping sickness, as has been shown for the ornithine decarboxylase inhibitor D,L-␣-difluoromethylornithine (3). We therefore investigated the trypanocidal activities of different peptidyl proteasome inhibitors against in vitrocultured bloodstream form T. brucei.
, and N-benzyloxycarbonyl-leucyl-leucyl-tyrosyl ␣-keto aldehyde (Z-Leu-Leu-Tyr-COCHO) were purchased from Bachem Biochemica GmbH (Heidelberg, Germany), and N-benzyloxycarbonyl-leucyl-leucyl-phenylalanal (Z-Leu-Leu-Phe-CHO) and Nbenzyloxycarbonyl-leucyl-leucyl-leucyl boronic acid [Z-Leu-LeuLeu-B(OH) 2 ] were purchased from Alexis Deutschland GmbH (Grünberg, Germany). All compounds have been shown previously to be inhibitors of the proteasome (8-10, 16, 17) .
Assays. Bloodstream form T. brucei (TC221) and human myeloid leukemia HL-60 cells were grown axenically as described previously (11) .
For toxicity tests, cells were seeded into 24-well plates at appropriate densities (10 4 trypanosomes/ml; 5 ϫ 10 4 HL-60 cells/ml) in 1 ml of medium containing various concentrations (10 Ϫ4 to 10 Ϫ12 M) of proteasome inhibitors dissolved in 100% dimethyl sulfoxide (DMSO). The controls contained DMSO alone. In all experiments, the final DMSO concentration was 1%, which had no effect on the cell growth (11) . After 48 h of incubation, living cells were counted with a Neubauer hemocytometer. The control cell counts were 10 6 trypanosomes/ml and 5 ϫ 10 5 HL-60 cells/ml. Each experiment was set up in duplicate and repeated three times.
For detection of apoptosis, cells were exposed to proteasome inhibitors at various concentrations for 24 h, harvested by centrifugation, and fixed overnight with 70% ethanol at Ϫ20°C. Then, cells were washed twice with HBSS (Hanks balanced salt solution) and 5 min with 900 l of HBSS plus 300 l of 200 mM Na 2 HPO 4 -100 mM citrate (pH 7.8) and stained with 200 l of HBSS containing 0.5 mg of RNase per ml and 0.5 g of propidium iodide per ml. After incubation for 30 min at room temperature, the DNA content of propidium iodide-stained cells was analyzed with a FACScan analytical cytometer using CellQuest Software (Becton Dickinson, Heidelberg, Germany). Cells from the sub-G 0 /G 1 peak were counted as apoptotic cells (14) .
Antitrypanosomal activities of proteasome inhibitors. Peptide aldehydes are the best-characterized inhibitors of the proteasome. These agents are substrate analogues, and cells are permeable to them. Previous studies have revealed that peptide aldehydes of the scaffold R-Leu-Leu-Xaa-CHO are the most potent inhibitors of the proteasome (1). Therefore, Ac-Leu-Leu-Nle-CHO, Ac-Leu-Leu-Met-CHO, Z-Leu-LeuLeu-CHO, Z-Leu-Leu-Phe-CHO, and Z-Leu-Leu-Tyr-COCHO were chosen to have their antitrypanosomal activities tested. Since peptide boronates are much more potent inhibitors of Ac-Leu-Leu-Nle-CHO 45 100,000 4,600 Ͼ100,000 Ac-Leu-Leu-Met-CHO 1,600 100,000 20,000 Ͼ100,000 Z-Ile-Glu(OtBu)-AlaLeu-CHO 0.086 40 36 100,000
Z-Leu-Leu-Leu-CHO 5.5 4,000 73 Ͼ100,000 Z-Leu-Leu-Phe-CHO 150 7,000 120 100,000 Z-Leu-Leu-Tyr-COCHO 720 100,000 3,000 Ͼ100,000 Z-Leu-Leu-Leu-B(OH) 2 0.32 10 1.1 1,000
a Values are the means of three independent experiments. The standard error never exceeded 30%. the proteasome (1, 8) , the trypanocidal activity of the boronate analogue of Z-Leu-Leu-Leu-CHO, Z-Leu-Leu-Leu-B(OH) 2 , was also investigated. Z-Ile-Glu(OtBu)-Ala-Leu-CHO was included in this study because this compound has been shown to inhibit the proteasome purified from T. brucei (13) . All seven compounds exhibited antitrypanosomal activities against bloodstream form T. brucei, with 50% effective doses (ED 50 s) and MICs varying 10,000-fold ( Table 1 ). The most trypanocidal proteasome inhibitors were Z-Ile-Glu(OtBu)-Ala-Leu-CHO and Z-Leu-Leu-Leu-B(OH) 2 , with ED 50 s of 0.086 and 0.32 nM and MICs of 40 and 10 nM, respectively. Thus, the antitrypanosomal activities of these two proteasome inhibitors are comparable to that of pentamidine isethionate, which is used to treat sleeping sickness (ED 50 range, 1 to 2.5 nM; MIC range, 5.8 to 35 nM [11] ).
The general cytotoxicities of the proteasome inhibitors were assayed with HL-60 cells (Table 1 ). All compounds were also active against the human cells, with ED 50 s ranging from 1.1 nM to 20 M. Encouragingly, the MICs of six compounds were Ն100 M, the highest concentration tested; only Z-Leu-LeuLeu-B(OH) 2 had a MIC of 1 M. However, the ED 50 and MIC ratios of cytotoxic to trypanocidal activities were found to be in a modest range for nearly all proteasome inhibitors (Table 2) . Only Z-Ile-Glu(OtBu)-Ala-Leu-CHO gave substantial ED 50 and MIC ratios, with values of 400 and 2,500, respectively. For comparison, anti-sleeping sickness drugs generally have higher ED 50 and MIC ratios (11) .
Proteasome inhibitors have been shown to induce apoptosis in many oncogenic cell types (17) , and trypanosomes have been reported to be able to undergo apoptosis (18) (19) (20) . This prompted us to investigate whether the growth-inhibitory effects of Z-Leu-Leu-Leu-B(OH) 2 and Z-Ile-Glu(OtBu)-AlaLeu-CHO, the two most toxic proteasome inhibitors studied (Table 1) , can be attributed to induction of apoptosis. Based on hypodiploid DNA content, only 45% of trypanosomes appeared as apoptotic cells compared to 90% of HL-60 cells after exposure to Z-Leu-Leu-Leu-B(OH) 2 or Z-Ile-Glu(OtBu)-AlaLeu-CHO for 24 h (Fig. 1) . The latter finding is in agreement with previous observations that treatment of HL-60 cells with proteasome inhibitors results in induction of apoptosis (6) . Since only half of the trypanosomes appeared as apoptotic cells after treatment with both compounds, it is questionable whether the trypanocidal effect of proteasome inhibitors can be actually ascribed to induction of programmed cell death in bloodstream form T. brucei. Targets other than, or in addition to, the proteasome may be affected (8, 17) .
Although the compounds investigated in this study are not suitable for clinical use because of their cytotoxic effects, the results provide evidence that inhibition of the proteasome represents a new approach for the development of antitrypanosomal drugs. This finding may also be exploited in the future by utilizing the wealth of information currently being generated on proteasome inhibitors as anticancer agents (8, 12, 15, 17) . For example, the relatively high trypanocidal activity of Z-LeuLeu-Leu-B(OH) 2 AC-Leu-Leu-Nle-CHO 102 Ͼ1 AC-Leu-Leu-Met-CHO 13 Ͼ1 Z-Ile-Glu(OtBu)-Ala-Leu-CHO 419 2,500 Z-Leu-Leu-Leu-CHO 13 Ͼ25 Z-Leu-Leu-Phe-CHO 0.8 14 Z-Leu-Leu-Tyr-COCHO 4 Ͼ1 Z-Leu-Leu-Leu-B(OH) 2 3 100
a ED 50 and MIC ratios were calculated from ED 50 s and MICs shown in Table 1. VOL. 46, 2002 46, NOTES 2039 on October 29, 2017 by guest http://aac.asm.org/ their substrate specificities (7), specific and nontoxic proteasome inhibitors are the rational choice for future antitrypanosomal drug development.
